Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Status:
Completed
Trial end date:
2019-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of
levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major
Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK)
data to guide dose selection for future pediatric studies of levomilnacipran.